102 related articles for article (PubMed ID: 31883360)
1. SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma.
Si X; Gao Z; Xu F; Zheng Y
Mol Carcinog; 2020 Mar; 59(3):257-264. PubMed ID: 31883360
[TBL] [Abstract][Full Text] [Related]
2. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.
Wouters J; Stas M; Gremeaux L; Govaere O; Van den Broeck A; Maes H; Agostinis P; Roskams T; van den Oord JJ; Vankelecom H
PLoS One; 2013; 8(10):e76550. PubMed ID: 24098529
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.
Duz MB; Karatas OF
Mol Biol Rep; 2021 Feb; 48(2):1393-1400. PubMed ID: 33506275
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Heat Shock Transcription Factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel.
Vydra N; Toma A; Glowala-Kosinska M; Gogler-Piglowska A; Widlak W
BMC Cancer; 2013 Oct; 13():504. PubMed ID: 24165036
[TBL] [Abstract][Full Text] [Related]
5. Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
Basu R; Baumgaertel N; Wu S; Kopchick JJ
Horm Cancer; 2017 Jun; 8(3):143-156. PubMed ID: 28293855
[TBL] [Abstract][Full Text] [Related]
6. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
[TBL] [Abstract][Full Text] [Related]
7. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Luo Y; Ellis LZ; Dallaglio K; Takeda M; Robinson WA; Robinson SE; Liu W; Lewis KD; McCarter MD; Gonzalez R; Norris DA; Roop DR; Spritz RA; Ahn NG; Fujita M
J Invest Dermatol; 2012 Oct; 132(10):2440-2450. PubMed ID: 22622430
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
9. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid increases the anticancer effect of paclitaxel by inducing differentiation of cancer stem cells in melanoma.
Wang YB; Sun B; Han B
Pharmazie; 2018 Dec; 73(12):729-732. PubMed ID: 30522558
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of the characteristics of side population cells in the human ovarian cancer cell line OVCAR-3].
Luo LJ; Zhao Z; Zeng JF; Liang B; Yang JX; Cao DY; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):281-5. PubMed ID: 22781115
[TBL] [Abstract][Full Text] [Related]
12. KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
Lin H; Yang G; Yu J; Wang J; Li Q; Guo S; Cao B
Biomed Pharmacother; 2018 Nov; 107():1205-1209. PubMed ID: 30257334
[TBL] [Abstract][Full Text] [Related]
13. Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance.
Balaji SA; Udupa N; Chamallamudi MR; Gupta V; Rangarajan A
PLoS One; 2016; 11(5):e0155013. PubMed ID: 27171227
[TBL] [Abstract][Full Text] [Related]
14. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.
Jeon HM; Sohn YW; Oh SY; Kim SH; Beck S; Kim S; Kim H
Cancer Res; 2011 May; 71(9):3410-21. PubMed ID: 21531766
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR‑200c‑3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
Chen J; Tian W; He H; Chen F; Huang J; Wang X; Chen Z
Oncol Rep; 2018 Dec; 40(6):3821-3829. PubMed ID: 30272330
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
[TBL] [Abstract][Full Text] [Related]
17. Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells.
Chen HH; Chang HH; Chang JY; Tang YC; Cheng YC; Lin LM; Cheng SY; Huang CH; Sun MW; Chen CT; Kuo CC
Free Radic Biol Med; 2017 Dec; 113():505-518. PubMed ID: 29080842
[TBL] [Abstract][Full Text] [Related]
18. The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.
Ji L; Liu X; Zhang S; Tang S; Yang S; Li S; Qi X; Yu S; Lu L; Meng X; Liu Z
Molecules; 2017 Oct; 22(11):. PubMed ID: 29072615
[TBL] [Abstract][Full Text] [Related]
19. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
[TBL] [Abstract][Full Text] [Related]
20. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
